With dengue cases continuing to rise across Asia due to factors such as changing climate conditions, increased urbanization, and population growth, a new regional collaboration has been launched to ...

Takeda stopped enrolling patients in the trial, again well short of its target, earlier this year. Like TAK-186, TAK-280 used Maverick’s prodrug technology to restrict activation to the tumor ...

Following a positive Phase 3 readout for rusfertide in Oncology in March 2025, the company anticipates a further two Phase 3 readouts in core therapeutic areas this fiscal year. Takeda chief ...

“At Takeda, we set out on a journey to build a best-in-class global communications organization, empowered by a team of exceptional professionals who I truly see as business leaders,” Belo said on ...

Takeda boosts profit margins with AI-driven growth, FY2024 guidance upgrade, share buyback plan & promising drug launches. Skip to content. Home page Seeking Alpha - Power to Investors.

Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, gastrointestinal (GI) and hematology, while pushing the Japanese company ...

Takeda Pharmaceutical teamed up with the Boston Celtics to raise awareness of rare diseases at the C’s-Cavaliers game on Friday at the TD Garden.

Julie Kim is set to replace Christophe Weber as the new chief executive officer of Takeda Pharmaceutical Co., becoming the first woman to lead the more than 240-year-old Japanese drugmaker.

In a post on her LinkedIn profile, Kim thanked Weber and Takeda’s leadership team for their support as she becomes the next in line to helm the drugmaker. “Today, nothing is changing and I remain ...

Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm of Japan's biggest drugmaker as the company upped its full-year profit outlook.

Julie Kim, 54, has been running Takeda’s U.S. operations since 2022 and will assume the role of CEO in June next year, subject to shareholder approval, the company said.

Christophe Weber will step down as CEO of Takeda next year, the company announced, following a dropoff in its share price over the last couple of years.